Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Jan 7, 2015	Biocept to Present at the 8th Annual OneMedForum SAN DIEGO, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to	View HTML Biocept to Present at the 8th Annual OneMedForum 9 KB
Toggle Summary Dec 17, 2014	Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells Biocept's CTC Test Identified Approximately 22 Percent of Women With Breast Cancer to Have HER2 Positive CTC After Disease Progression Following a HER2 Negative Diagnosis With Solid Tumor Biopsy	View HTML Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells 13.2 KB
Toggle Summary Dec 15, 2014	Biocept Expands Worldwide Microchannel Patent Protection to South Korea Korean Patent Includes Microfluidic Channel for Capturing Circulating Tumor Cells	View HTML Biocept Expands Worldwide Microchannel Patent Protection to South Korea 23.1 KB
Toggle Summary Dec 3, 2014	Biocept Appoints Experienced Physician as Medical Director Veena Singh, MD, FCAP, FACMG Brings Years of Medical Experience to Biocept Team	View HTML Biocept Appoints Experienced Physician as Medical Director 23.6 KB
Toggle Summary Nov 13, 2014	Biocept Reports Third Quarter 2014 Financial Results SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30,	View HTML Biocept Reports Third Quarter 2014 Financial Results 25.3 KB
Toggle Summary Nov 12, 2014	Biocept Launches Lung Cancer Offering Blood-Based Liquid Biopsy Testing Launched for NSCLC Indications	View HTML Biocept Launches Lung Cancer Offering 17 KB
Toggle Summary Nov 6, 2014	Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for	View HTML Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results 12.5 KB
Toggle Summary Oct 13, 2014	Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel , Oct. 13, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd.	View HTML Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells 18.5 KB
Toggle Summary Oct 7, 2014	Biocept Expands Collaboration With MD Anderson Cancer Center Biocept's OncoCEE(TM) Platform Enhances Ovarian Cancer Research	View HTML Biocept Expands Collaboration With MD Anderson Cancer Center 13.3 KB
Toggle Summary Sep 30, 2014	Biocept to Present at the 13th Annual BIO Investor Forum SAN DIEGO , Sept. 30, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall , Biocept President and CEO, is scheduled to	View HTML Biocept to Present at the 13th Annual BIO Investor Forum 10 KB

Investor Relations

Press Releases

Contact Biocept, Inc.